| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
33,627 |
28,788 |
$2.54M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
4,690 |
4,260 |
$551K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,637 |
7,756 |
$481K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,028 |
5,221 |
$214K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,060 |
953 |
$115K |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
5,756 |
4,728 |
$83K |
| 80305 |
|
3,012 |
2,659 |
$25K |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
2,191 |
1,921 |
$25K |
| 99484 |
|
2,158 |
1,913 |
$22K |
| 93922 |
|
436 |
387 |
$21K |
| 95923 |
|
434 |
387 |
$19K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
306 |
267 |
$18K |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
4,660 |
3,634 |
$17K |
| 95921 |
|
435 |
388 |
$17K |
| 96127 |
|
4,448 |
4,040 |
$15K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
2,593 |
2,251 |
$14K |
| 99439 |
|
429 |
416 |
$14K |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
1,252 |
1,107 |
$13K |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
3,304 |
2,738 |
$12K |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
5,399 |
4,148 |
$9K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
103 |
89 |
$7K |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
1,277 |
1,108 |
$6K |
| G8482 |
Influenza immunization administered or previously received |
1,424 |
1,233 |
$5K |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
565 |
485 |
$5K |
| 96138 |
|
329 |
317 |
$5K |
| G0396 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes |
168 |
157 |
$5K |
| 96132 |
|
298 |
285 |
$4K |
| 99490 |
Ccm add 20min |
748 |
713 |
$4K |
| L0648 |
Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
16 |
16 |
$3K |
| 96130 |
|
167 |
161 |
$2K |
| 1124F |
|
2,405 |
2,140 |
$2K |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
1,193 |
984 |
$1K |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
232 |
221 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12 |
12 |
$1K |
| G8734 |
Elder maltreatment screen documented as negative, follow-up is not required |
230 |
218 |
$888.83 |
| 3725F |
|
881 |
806 |
$856.83 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
5,316 |
3,652 |
$677.60 |
| 1123F |
|
1,026 |
937 |
$610.57 |
| G9717 |
Documentation stating the patient has had a diagnosis of bipolar disorder |
87 |
85 |
$505.74 |
| 96160 |
|
100 |
81 |
$333.82 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
295 |
268 |
$320.29 |
| 0518F |
|
114 |
111 |
$69.50 |
| G8484 |
Influenza immunization was not administered, reason not given |
178 |
164 |
$51.15 |
| 1100F |
|
112 |
109 |
$22.66 |
| 98981 |
|
280 |
269 |
$0.00 |
| 98980 |
|
453 |
421 |
$0.00 |
| 98977 |
|
342 |
341 |
$0.00 |
| 98975 |
|
83 |
83 |
$0.00 |